Calcium Hydroxylapatite Filler: An Overview of Safety and Tolerability
September 2013 | Volume 12 | Issue 9 | Original Article | 996 | Copyright © 2013
Tatjana Pavicic MD
Ludwig-Maximilian University of Munich, Munich, Germany
Soft tissue fillers are becoming increasingly important as nonsurgical treatment options for facial rejuvenation. Calcium hydroxylapatite (CaHA) is an injectable dermal filler that contains uniform CaHA microspheres suspended in an aqueous carboxymethylcellulose gel carrier. It is considered a long-lasting, but non-permanent filler, and is highly biocompatible with human tissue. No osteogenesis has been reported in extensive literature describing the use of CaHA in a variety of soft tissue applications. Injection of CaHA into the oral mucosa and the lips is an unapproved indication and may result in nodule formation. This occurs soon after injection and is a result of accumulated particles and not a granulomatous reaction. As with all biodegradable dermal fillers, CaHA can be associated with rare incidences of foreign body reactions, but only a handful of case reports have been documented in 10 years of clinical use. CaHA can be associated with local, short-term, injection-related adverse events, which are generally mild and resolve within a few days. Clinical trials that have followed patients for up to 3 years post-injection report no long-term or delayed-onset adverse events. CaHA is an effective and safe treatment option for a variety of aesthetic indications. This paper focuses on common safety concerns of patients and aesthetic physicians, including unfounded fears of osteogenesis and foreign body granulomas, providing an up-to-date overview of the tolerability and long-term safety of CaHA for aesthetic indications.
J Drugs Dermatol. 2013;12(9):996-1002.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Facial rejuvenation procedures, which are minimally invasive and provide a long-lasting visible improvement, are rapidly increasing in popularity.1,2 In recent years, the recognition that facial volume loss plays an important role in the aging process, has shifted the focus of treatment from a concentration on isolated problem areas to targeting the entire face for a more harmonious and natural effect.3-5 Dermal fillers give the face a fuller, more youthful appearance and have become a popular means of addressing volume loss and contour defects resulting from ageing, disease, or trauma. As their popularity increases, so too has the number of products available. However, regulation of the industry varies considerably between countries. Pharmaceutical products achieve their principal action by pharmacological, metabolic or immunological changes within or on the body. Dermal fillers are classified as medical devices by most regulatory agencies, including the US Food and Drug Administration (FDA) as their primary intended action is mechanical (filling effect) and not pharmacological.In Europe, dermal fillers are also considered as medical devices, but they only require a European CE Mark that does not demand the conduction of clinical studies for approval to commence sales. In contrast, prescription only medicines such as botulinum toxin require a marketing license from the Medicines and Healthcare products Regulatory Agency (MHRA). In the USA, FDA approval is based on the review of data collected from controlled clinical studies of at least 6 months duration that have evaluated the safe and effective use of dermal fillers when injected into specified areas of facial tissue and in comparison with an established FDA-approved agent.
Benefit versus safety is a key consideration for any therapeutic product. Calcium hydroxylapatite (CaHA [Radiesse®]; Merz Pharmaceuticals GmbH, Frankfurt, Germany) received FDA approval in 2006 for facial soft tissue augmentation including the correction of moderate to severe nasolabial folds, and the restoration and correction of the signs of HIV-associated facial lipodystrophy. In Europe, CaHA received a CE mark in 2004 for plastic and reconstructive surgery, including deep dermal and subdermal soft tissue augmentation of the facial area. Since then it has been extensively used for the correction of moderate to severe facial lines and folds and to replenish lost volume. It is one of the most well-studied dermal fillers with more than 4 million syringes injected worldwide. This paper focuses on common safety concerns of patients and aesthetic physicians, including unfounded fears of osteogenesis and foreign body granulomas, providing an up-to-date overview of the tolerability and long-term safety of CaHA for aesthetic indications.
Mechanism of Action
CaHA is a biodegradable filler composed of synthetically produced smooth, uniform CaHA microspheres (diameter of 25-45 μm) suspended in a sodium carboxymethylcellulose gel carrier combined in a ratio of 30% microspheres to 70% gel by volume. The gel carrier suspends the particles and allows them to be de-